Our study days are sponsored by pharmaceutical companies, who provide funding that allows us to offer all events completely free of charge. Sponsors have no involvement in agenda development, speaker selection, or clinical content – this is managed entirely by MORPh’s clinical team.
The “Pharmacy Workforce Development in Primary Care” Study Day is free to access for all registered healthcare professionals that have a MORPh Account.
Doors will open at 09:00 for welcome and introductions the study day will begin shortly after. Our expert speakers will be discussing the following topics:
Learning ObjectivesÂ
- Develop sustainable pharmacy workforce models aligned to PCN clinical priorities including CVD and Serious Mental Illness.Â
- Design and implement pharmacist-led clinics that demonstrably improve QoF performance and DES delivery.Â
- Deliver structured mental health medication reviews covering depression, anxiety and SMI safely and confidently.Â
- Optimise cardiometabolic risk management in patients with Serious Mental Illness to reduce health inequalities.Â
- Reduce high-risk psychotropic prescribing through structured deprescribing and monitoring frameworks.Â
- Demonstrate the strategic and financial value of pharmacist-led services within MDT settings.Â
Workforce Planning & Strategy: Making the Most of the Pharmacy TeamÂ
- Strategic workforce planning & moving beyond mandated pathwaysÂ
- Aligning ARRS pharmacists to priority areas: CVD & lipid optimisation, Pain management, Respiratory care, SMI clinicsÂ
- Retention and Career Progression: Supporting pharmacists post-IP qualification, developing specialist interests (CVD, SMI, LTCs), Portfolio and leadership pathwaysÂ
- Embedding Foundation & Trainee Pharmacists: Designing meaningful placements & linking trainee development to QoF and DES deliveryÂ
- Structured supervision modelsÂ
- Measuring workforce impact: improving QOF, reducing GP workload, DES compliance, ARRS investment returnÂ
Creating Pharmacy Team Led Clinics with ImpactÂ
- Integrating the MDT and protecting clinical scope: defining pharmacist-led clinic boundaries, avoiding duplication, governance frameworks for safe prescribingÂ
- Designing high impact clinics for example for CVD, HTN, pain management, respiratory and SMR health checksÂ
- SMI as a core population health priority and how pharmacists can help: Cardiometabolic risk in SMI patients and integrating BP, lipid and diabetes optimisation into SMI reviewsÂ
- Building business cases and demonstrating value to your practice: QoF MH indicator performance, CVD QoF crossover, high-risk prescribing reduction, reduced secondary care admissionsÂ
SMRs in Depression, Anxiety and SMIÂ
- Depression & Anxiety: PHQ-9 and GAD-7 use, Suicide risk assessment, Safe SSRI initiation and switching, Long-term antidepressant reviewÂ
- Serious Mental Illness (SMI): recognising bipolar disorder & psychosis red flags, when not to prescribe antidepressants, safe shared-care antipsychotic prescribingÂ
- Medicines Optimisation: Benzodiazepine and hypnotic deprescribing, polypharmacy in mental health, drug interactions and physical health monitoringÂ
SMI Physical Health, Cardiometabolic Risk & Population Health ImpactÂ
- SMI Annual Health Checks: BP, BMI, HbA1c, lipids, Smoking status, Antipsychotic monitoring requirementsÂ
- Cardiovascular Risk in SMI: QRISK in SMI populations, statin optimisation, Hypertension management, Integrating CRM principlesÂ
- Identifying SMI Cohorts Using EMIS/SystmOne: Overdue physical health reviews, Poor CVD control, High-risk psychotropic prescribingÂ
- Demonstrating Impact to PCNs: QoF MH indicator improvement, CVD QoF crossover improvement, reduced admissions, addressing health inequalitiesÂ
